Corrective Steps Were Taken Immediately; Involved No Stoppage Of Product Shipments MINNEAPOLIS, March 24, 1999 -- Chronimed Inc. (Nasdaq: CHMD), acknowledged today that it received a warning letter from the Food & Drug Administration (FDA) regarding its Eden Prairie, MN production facility.
Chronimed Inc. and its subsidiary companies Statscript Pharmacy, Clinical Partners, Inc., and Home Service Medical (collectively, the “Company”) have undertaken a Year 2000 readiness program to address the various issues surrounding Year 2000 date processing.
MINNEAPOLIS, March 8, 1999 -- Chronimed Inc. (Nasdaq: CHMD), a leading manufacturer and distributor of diagnostic products since 1985, announced today that it has commenced an action against Bayer Corporation in Minneapolis federal court. The declaratory judgment action seeks a ruling that
MINNEAPOLIS, March 3, 1999 -- Chronimed Inc. (Nasdaq: CHMD), announced today that Gregory H. Keane has been promoted to vice president, finance from corporate controller. Prior to joining Chronimed three years ago, Keane was employed by National Computer Systems where he served as controller, and
MINNEAPOLIS, January 26, 1999 -- Chronimed Inc. (Nasdaq: CHMD) , today announced record second quarter revenue and net income for the period ended January 1, 1999. Chronimed reported record revenue for the second quarter ended January 1, 1999 of $48.7 million, up 40 percent from $34.8 million in
MINNEAPOLIS, January 25, 1999 -- Chronimed Inc. (Nasdaq: CHMD), announced today that the Food and Drug Administration (FDA) has cleared the Lasette™ laser finger perforator system for use in drawing blood for screening purposes. Previously cleared for blood glucose testing purposes, the Lasette is
MINNEAPOLIS, January 12, 1999 -- Chronimed Inc. (Nasdaq: CHMD) , today made a presentation to investors at the Hambrecht & Quist 17th Annual Healthcare Conference in San Francisco. Chronimed is a leading integrated healthcare company specializing in diagnostic products, pharmacy services and
New Program Has the Potential to Reduce Preventable Healthcare Costs Due to Non-Compliance By Millions of Dollars NEWS RELEASE MINNEAPOLIS, January 11, 1999 -- Chronimed Inc. (Nasdaq: CHMD), announced today the launch of The Life Management ProgramSM for Transplant Members, a program that will, if
MINNEAPOLIS, October 21, 1998 -- Chronimed Inc. (Nasdaq: CHMD) , today announced first quarter revenue and net income for the period ended October 2, 1998. Chronimed reported record revenue for the first quarter ended October 2, 1998 of $42.8 million, up 35 percent from $31.7 million in last year's
